biotinylated antibodies against human cd3  (Miltenyi Biotec)

Journal: Nature Communications

Article Title: IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates

doi: 10.1038/s41467-018-06804-y

Figure Lengend Snippet: Antagonist anti-IL-7Rα mAb inhibits antigen-specific human memory T cells persistence after antigen rechallenge. Human CPD-labeled PBMCs ( n = 4) were stimulated with MHCI or MHCII -restricted pool of peptides (H1N1 flu; CEFT: CMV, EBV, Flu, Tetanos; CEF: CMV, EBV, Flu) or with anti-CD3 + anti-CD28 mAbs for 3 days ( a ), 8 days ( b ) or 10 days ( c ). Cells were cultured in medium alone (white histogram) or supplemented with 5 ng/ml of recombinant human IL-7 (black histogram) or 5 ng/mL of human IL-7 plus 10 µg/ml of the site-1/2b humanized anti-IL-7Rα mAb (grey histogram). The histograms show the percentage of proliferated cells (% of CPD low cells) and viable cells (% of Annexin-V − PI − cells) among total cells, or within proliferated (CPDlow, Fig. 7c middle) versus quiescent (CPD high, Fig. 7c right) cells. Horizontal bars mean ± SEM. * p < 0.05 between indicated groups

Article Snippet: T cells were analyzed with or without over-night activation in 24-well plates (5 × 10 5 T cells/well) with a T cell Activation/Expansion kit from Miltenyi that consists of AntiBiotin MACSiBead™ Particles and biotinylated antibodies against non-human primate CD3 and human CD2 and CD28.

Techniques: Labeling, Cell Culture, Recombinant